Managed Care Research in Action

(R3) Podium Session – Award-winning Research Supporting the Managed Care Pharmacy Research Agenda

Wednesday, March 22, 2023

3:15 PM – 4:30 PM

Location: 302AB

ACPE UAN:N/A | Contact Hours: N/A | Activity Type: N/A

Faculty(s)

Carmela Benson, MS, MSHP

Group Director, Real-World Value and Evidence
Janssen Scientific Affairs, LLC
Titusville, NJ
Jennifer Pigoga, PhD, MPH, MSc (she/her/hers)

Lead Data Scientist
CVS Health Clinical Trial Services
Blue Bell, PA
Kayce Shealy, PharmD, BCPS, CDCES (she/her/hers)

Professor, Pharmacy Practice
Presbyterian College School of Pharmacy
Clinton, SC
Ben Urick, PharmD, PhD

Health Outcomes Research Principal
Prime Therapeutics, LLC
Chapel Hill, NC

Moderator(s)

Laura Happe, PharmD, MPH

Associate Professor, Editor-in-Chief
University of Florida, Journal of Managed Care and Specialty Pharmacy
Cornelius, North Carolina

AMCP and the AMCP Foundation jointly developed a Managed Care Pharmacy Research Agenda to inspire research in high priority areas with a significant potential to improve health care quality – for all. The agenda identified for research pillars: (1) real-world evidence to inform managed care pharmacy decision-making, (2) value-based models in managed care pharmacy to address total cost of care, (3) impact of benefit design or utilization management strategies on patient outcomes, and (4) impact of direct patient care services provided by managed care pharmacy on patient outcomes.

In this podium session, authors of the top-rated abstracts aligned to each of these research pillars will present and discuss their findings.

The platinum abstract award presentations are:

• The effects of COVID-19 on first-time initiation of anti-depressant and anti-anxiety medication among U.S. adolescents and young adults enrolled in a large commercial health plan

• Estimating Medical Cost Offsets from Continuous Adherence Improvement Using Commercially Insured Members’ Real-World Data

• Treatment patterns and healthcare resource utilization following the reversal/rejection/payment of the initial once-monthly Paliperidone Palmitate long-acting injectable antipsychotic claim among patients with schizophrenia/schizoaffective disorder

• Pharmacy and public health partnership to expand team-based care in rural South Carolina

Learning Objectives::

At the completion of this activity, participants should be able to:

Describe changes in initiation of antianxiety and antidepressant by adolescents and young adults during the COVID-19 pandemic.
Understand an approach to developing estimates for medical cost offsets from improvements in continuous adherence.
Understand the potential unintended outcomes for patients diagnosed with schizophrenia (SCZ) or schizoaffective disorder (SCA) after rejection or reversal of their initial claim of once-monthly paliperidone palmitate (PP1M).
Describe the impact of integrating pharmacists into rural South Carolina primary care practices.